WO2004032837A3 - Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine - Google Patents

Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine Download PDF

Info

Publication number
WO2004032837A3
WO2004032837A3 PCT/US2003/031378 US0331378W WO2004032837A3 WO 2004032837 A3 WO2004032837 A3 WO 2004032837A3 US 0331378 W US0331378 W US 0331378W WO 2004032837 A3 WO2004032837 A3 WO 2004032837A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine
inhibiting
bind
activity
mutein
Prior art date
Application number
PCT/US2003/031378
Other languages
English (en)
Other versions
WO2004032837A2 (fr
Inventor
Charles A Dinarello
Soo-Hyun Kim
Philip Bufler
Original Assignee
Ares Trading Sa
Charles A Dinarello
Soo-Hyun Kim
Philip Bufler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0315155-7A priority Critical patent/BR0315155A/pt
Priority to ES03756906T priority patent/ES2416510T3/es
Priority to MXPA05003869A priority patent/MXPA05003869A/es
Priority to CA2500577A priority patent/CA2500577C/fr
Priority to EP03756906A priority patent/EP1572291B1/fr
Priority to AU2003299919A priority patent/AU2003299919B2/en
Application filed by Ares Trading Sa, Charles A Dinarello, Soo-Hyun Kim, Philip Bufler filed Critical Ares Trading Sa
Priority to EA200500617A priority patent/EA008667B1/ru
Priority to JP2004543122A priority patent/JP4563813B2/ja
Publication of WO2004032837A2 publication Critical patent/WO2004032837A2/fr
Priority to IL167769A priority patent/IL167769A/en
Priority to NO20052203A priority patent/NO337024B1/no
Publication of WO2004032837A3 publication Critical patent/WO2004032837A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention se rapporte à l'utilisation d'une cytokine-1, de préférence de la famille IL-1 et mieux encore, de la famille IL-1F7b, ou d'un isoforme, d'une mutéine, d'une protéine fusionnée, d'un dérivé fonctionnel ou d'un fragment de celui-ci, pouvant se fixer à IL-18 BP ou d'une muteine, d'une protéine fusionnée, d'un dérivé fonctionnel ou d'un fragment de celui-ci pouvant inhiber un récepteur de cytokine-2, cytokine-2 étant un élément de la famille IL-1, de préférence IL-18, dans la production d'un médicament pour le traitement ou pour la prévention d'une maladie provoquée ou aggravée par induction dudit récepteur de cytokine-2.
PCT/US2003/031378 2002-10-08 2003-10-03 Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine WO2004032837A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES03756906T ES2416510T3 (es) 2002-10-08 2003-10-03 Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina
MXPA05003869A MXPA05003869A (es) 2002-10-08 2003-10-03 El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
CA2500577A CA2500577C (fr) 2002-10-08 2003-10-03 Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine
EP03756906A EP1572291B1 (fr) 2002-10-08 2003-10-03 Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine
AU2003299919A AU2003299919B2 (en) 2002-10-08 2003-10-03 The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
BR0315155-7A BR0315155A (pt) 2002-10-08 2003-10-03 Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
EA200500617A EA008667B1 (ru) 2002-10-08 2003-10-03 Применение цитокина, способного связывать il-18bp и ингибировать активность второго цитокина
JP2004543122A JP4563813B2 (ja) 2002-10-08 2003-10-03 Ｉｌ−１８ｂｐに結合でき、第２サイトカインの活性を阻害するサイトカインの使用
IL167769A IL167769A (en) 2002-10-08 2005-03-31 Use of il-1f7b that links il-18r with il-1bp in the preparation of drugs
NO20052203A NO337024B1 (no) 2002-10-08 2005-05-04 Anvendelse av cytokin-1 IL-1F7b som kan binde IL-18BP, for fremstilling av et medikament for behandling eller forebygging av inflammatoriske sykdommer, samt en vektor som koder for nevnte cytokin og anvendelse av nevnte vektor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41682702P 2002-10-08 2002-10-08
US60/416,827 2002-10-08

Publications (2)

Publication Number Publication Date
WO2004032837A2 WO2004032837A2 (fr) 2004-04-22
WO2004032837A3 true WO2004032837A3 (fr) 2006-04-13

Family

ID=32093906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031378 WO2004032837A2 (fr) 2002-10-08 2003-10-03 Utilisation de cytokine pouvant se fixer a il-18bp et inhiber l'activite d'une seconde cytokine

Country Status (15)

Country Link
US (2) US7279155B2 (fr)
EP (1) EP1572291B1 (fr)
JP (1) JP4563813B2 (fr)
KR (1) KR101015682B1 (fr)
CN (1) CN1909926A (fr)
AU (1) AU2003299919B2 (fr)
BR (1) BR0315155A (fr)
CA (1) CA2500577C (fr)
EA (1) EA008667B1 (fr)
ES (1) ES2416510T3 (fr)
IL (1) IL167769A (fr)
MX (1) MXPA05003869A (fr)
NO (1) NO337024B1 (fr)
UA (1) UA86750C2 (fr)
WO (1) WO2004032837A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
KR101015682B1 (ko) * 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Ｉｌ-18ｂｐ에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2006208241B2 (en) * 2005-01-25 2011-08-04 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
WO2008147869A2 (fr) * 2007-05-22 2008-12-04 Centocor, Inc. Marqueurs et procédé permettant d'évaluer et traiter la maladie de crohn et les troubles associés
EP3265807A1 (fr) * 2015-03-05 2018-01-10 AB2 Bio SA Protéine de liaison à l'il-18 (il-18 bp) et anticorps dans des maladies inflammatoires
EP3600429B1 (fr) * 2017-03-20 2023-10-25 Bio-Techne Corporation Protéine de fusion de l'il-37 et procédés de fabrication et d'utilisation de celle-ci
BR112020004389A2 (pt) * 2017-09-06 2020-09-08 Yale University composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
KR0176693B1 (ko) 1989-12-22 1999-04-01 레지널드 디. 쇼트보그; 제롬 반 쥘렌 조절요소를 사용한 내인성 유전자의 발현을 변형시키는 방법
DK0554381T3 (da) * 1990-10-25 1996-04-09 Genentech Inc Anvendelse af beskyttende midler mod reaktive oxygenforbindelser
JP2864434B2 (ja) 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
US5945310A (en) * 1997-05-19 1999-08-31 Smithkline Beecham Corporation DNA encoding members of the IL-1 family, IL-1 delta
US7220717B2 (en) * 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
PT1047781E (pt) * 1998-01-23 2004-11-30 Immunex Corp Receptores de il-18
US6342371B1 (en) * 1999-04-16 2002-01-29 Smithkline Beecham Corporation Interleukin-1 homologue, IL-1H4
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EP1233977A1 (fr) * 1999-12-01 2002-08-28 SmithKline Beecham Corporation Homologue d'interleukine-1, mat il-1h4
WO2002032374A2 (fr) 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18
KR101015682B1 (ko) * 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Ｉｌ-18ｂｐ에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUFLER P. ET AL: "A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity", PNAS, vol. 99, no. 21, October 2002 (2002-10-01), pages 13723 - 13728, XP008070064 *
KUMAR S. ET AL: "Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production", CYTOKINE, vol. 18, no. 2, April 2002 (2002-04-01), pages 61 - 71, XP008070058 *
NOVICK D. ET AL: "Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response", IMMUNITY, vol. 10, January 1999 (1999-01-01), pages 127 - 136, XP000973488 *
PAN G. ET AL: "IL-1H, an Interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp", CYTOKINE, vol. 13, no. 1, January 2001 (2001-01-01), pages 1 - 7, XP002212905 *
See also references of EP1572291A4 *

Also Published As

Publication number Publication date
KR20050074470A (ko) 2005-07-18
EP1572291A2 (fr) 2005-09-14
CA2500577A1 (fr) 2004-04-22
JP2006516953A (ja) 2006-07-13
ES2416510T3 (es) 2013-08-01
EP1572291B1 (fr) 2013-04-03
US7279155B2 (en) 2007-10-09
CN1909926A (zh) 2007-02-07
MXPA05003869A (es) 2005-06-22
KR101015682B1 (ko) 2011-02-22
NO20052203L (no) 2005-05-04
UA86750C2 (ru) 2009-05-25
US7820156B2 (en) 2010-10-26
JP4563813B2 (ja) 2010-10-13
NO20052203D0 (no) 2005-05-04
EP1572291A4 (fr) 2009-06-24
CA2500577C (fr) 2013-12-17
AU2003299919A1 (en) 2004-05-04
EA200500617A1 (ru) 2006-08-25
WO2004032837A2 (fr) 2004-04-22
AU2003299919B2 (en) 2009-08-06
US20090074710A1 (en) 2009-03-19
NO337024B1 (no) 2016-01-04
EA008667B1 (ru) 2007-06-29
US20040120923A1 (en) 2004-06-24
IL167769A (en) 2013-10-31
BR0315155A (pt) 2005-08-16

Similar Documents

Publication Publication Date Title
NO20052203D0 (no) Anvendelse av cytokin som kan binde IL-18BP og inhibere aktiviteten til et andre cytokin
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
IL199914B (en) Use of protein kinase n beta to produce a diagnostic agent
NO20062148L (no) Antistoffer som binder interleukin-4-reseptor
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
WO2002089738A3 (fr) Composes proteomimetiques et procedes correspondants
HK1073653A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates and method of preparation
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
BG110174A (en) Substituted arylpyrazines
TW200611695A (en) Pyrrolopyridine derivatives
WO2006058867A3 (fr) Pteridines substituees pour le traitement de maladies inflammatoires
WO2004094473A3 (fr) Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
CY1112673T1 (el) Φαινοξυ αιθερες αμινοξεων
WO2007051785A3 (fr) Utilisation de sdf-1 pour le traitement et/ou la prevention de maladies neurologiques
AU2003260436A1 (en) Pyrimidine compounds
WO2005113017A3 (fr) Therapie genique a base de gfap pour le traitement des maladies de la retine
CA2380216A1 (fr) Utilisation d'inhibiteurs de il-18
WO2004100882A3 (fr) Inhibition de medicament se liant a la serumalbumine
AU2016202280A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
WO2004041296A3 (fr) Composition pharmaceutique comportant un antagoniste de facteur tissulaire et des polypeptides de la proteine c
WO2006044294A3 (fr) Analogues de la proteine humaine c
WO2002070557A3 (fr) Domaine de liaison du ligand du recepteur hormonal nucleaire
WO2005035564A3 (fr) Variants de tnf-alpha a base proteique destines au traitement de troubles associes au tnf-alpha
WO2006128911A3 (fr) Utilisation d'isoformes d'il-18bp dans le traitement et/ou la prevention de maladies inflammatoires neurologiques
WO2004101618A3 (fr) Proteines associees au recepteur de progestine yol002c-cgi-45

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003299919

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003756906

Country of ref document: EP

Ref document number: 2500577

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 167769

Country of ref document: IL

Ref document number: 1020057005571

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004543122

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003869

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200500617

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038A48949

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057005571

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003756906

Country of ref document: EP